Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorShanghai East Hospital
About this trial
In this study, the investigators intend to utilize 68Ga-Pentixafor Positron Emission Tomography（PET） imaging for patients diagnosed with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The investigators will compare the imaging results with those obtained from 18F-FDG imaging, and a correlation analysis will be performed to assess progression-free survival among patients. This analysis aims to evaluate the diagnostic efficacy and the potential for early prediction of treatment efficacy associated with 68Ga-Pentixafor in these specific conditions.
Eligibility criteria
Qualifiers
Age of 18 years or older
ECOG < 2
Newly diagnosed patients with NHL and MM who have been confirmed or are highly suspected based on pathological examination
Completion of 18F-FDG PET/CT or PET/MR imaging within the past week in our department
Disqualifiers
Pregnant and breastfeeding women;
Individuals with severe hepatic and renal failure;
Patients with concurrent malignancies;
Individuals unable to remain supine for a duration of 30 minutes to complete the examination;
Trial design
Treatments tested in this trial
- Not listed
Trial groups
30 Participants
are grouped into 1 trial groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov